Aby J. Mathew Sells 630 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

Key Points

• Aby Mathew, EVP of BioLife Solutions, sold 630 shares of the company's stock for approximately $16,902.90, reducing his ownership by 0.18% while retaining 351,421 shares valued at over $9.4 million.
• BioLife Solutions reported a loss of $0.33 per share for the latest quarter, significantly missing the expected loss of $0.02, although its revenue of $25.42 million exceeded forecasts.
• The stock has shown significant trading activity recently, with shares reaching $25.80 on Monday and a market capitalization of $1.24 billion, reflecting a 50-day moving average of $23.47.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 630 shares of the company's stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $26.83, for a total value of $16,902.90. Following the transaction, the executive vice president directly owned 351,421 shares in the company, valued at approximately $9,428,625.43. This represents a 0.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

BioLife Solutions Stock Performance

BLFS traded down $0.71 during trading on Friday, hitting $25.57. 562,596 shares of the stock were exchanged, compared to its average volume of 395,316. The firm has a 50 day simple moving average of $23.83 and a 200 day simple moving average of $23.35. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -213.07 and a beta of 1.78. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.31). The firm had revenue of $25.42 million for the quarter, compared to analysts' expectations of $23.71 million. BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BLFS has been the topic of several recent research reports. Zacks Research raised BioLife Solutions to a "strong-buy" rating in a research report on Monday, August 11th. Stephens initiated coverage on BioLife Solutions in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 target price on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price (up previously from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of "Buy" and a consensus target price of $31.29.

Institutional Trading of BioLife Solutions

Several hedge funds and other institutional investors have recently made changes to their positions in BLFS. T. Rowe Price Investment Management Inc. purchased a new stake in shares of BioLife Solutions during the 1st quarter valued at $30,789,000. Royal Bank of Canada lifted its holdings in shares of BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider's stock valued at $15,948,000 after purchasing an additional 617,320 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of BioLife Solutions during the 4th quarter valued at $11,113,000. Millennium Management LLC lifted its holdings in shares of BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock valued at $29,733,000 after purchasing an additional 377,111 shares during the last quarter. Finally, Invesco Ltd. raised its stake in BioLife Solutions by 9.6% in the 1st quarter. Invesco Ltd. now owns 3,551,054 shares of the medical equipment provider's stock worth $81,106,000 after acquiring an additional 311,585 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.